 Atypical Hemolytic Uremic Syndrome
"Atypical Hemolytic Uremic Syndrome" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An hereditary hemolytic uremic syndrome associated with variations in the gene that encodes COMPLEMENT FACTOR H, or the related proteins CFHR1 and CFHR3. Disease often progresses to CHRONIC KIDNEY FAILURE without the prodromal symptoms of ENTEROCOLITIS and DIARRHEA that characterize typical hemolytic uremic syndrome.
| Descriptor ID |
D065766
|
| MeSH Number(s) |
C12.777.419.936.463.500 C13.351.968.419.936.463.500 C15.378.071.141.610.500 C15.378.140.855.925.500.500
|
| Concept/Terms |
Atypical Hemolytic Uremic Syndrome- Atypical Hemolytic Uremic Syndrome
- Non-Stx-Hus
- Non Stx Hus
- Non-Shiga-Like Toxin-Associated HUS
- HUS, Non-Shiga-Like Toxin-Associated
- HUSs, Non-Shiga-Like Toxin-Associated
- Non Shiga Like Toxin Associated HUS
- Non-Shiga-Like Toxin-Associated HUSs
- Toxin-Associated HUS, Non-Shiga-Like
- Toxin-Associated HUSs, Non-Shiga-Like
- Hemolytic Uremic Syndrome, Atypical
- Nonenteropathic HUS
- HUS, Nonenteropathic
- HUSs, Nonenteropathic
- Nonenteropathic HUSs
- Atypical Hemolytic-Uremic Syndrome
- Atypical Hemolytic-Uremic Syndromes
- Hemolytic-Uremic Syndrome, Atypical
- Hemolytic-Uremic Syndromes, Atypical
- Syndrome, Atypical Hemolytic-Uremic
- Syndromes, Atypical Hemolytic-Uremic
|
Below are MeSH descriptors whose meaning is more general than "Atypical Hemolytic Uremic Syndrome".
Below are MeSH descriptors whose meaning is more specific than "Atypical Hemolytic Uremic Syndrome".
This graph shows the total number of publications written about "Atypical Hemolytic Uremic Syndrome" by people in this website by year, and whether "Atypical Hemolytic Uremic Syndrome" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2010 | 0 | 1 | 1 | | 2014 | 0 | 1 | 1 | | 2016 | 0 | 1 | 1 | | 2017 | 1 | 0 | 1 | | 2018 | 3 | 0 | 3 | | 2020 | 2 | 1 | 3 | | 2022 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Atypical Hemolytic Uremic Syndrome" by people in Profiles.
-
Dixon BP, Sabus A. Ravulizumab 100 mg/mL formulation reduces infusion time and frequency, improving the patient and caregiver experience in the treatment of atypical haemolytic uraemic syndrome. J Clin Pharm Ther. 2022 Jul; 47(7):1081-1087.
-
Ariceta G, Dixon BP, Kim SH, Kapur G, Mauch T, Ortiz S, Vallee M, Denker AE, Kang HG, Greenbaum LA. The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment. Kidney Int. 2021 07; 100(1):225-237.
-
Poppelaars F, Thurman JM. Complement-mediated kidney diseases. Mol Immunol. 2020 12; 128:175-187.
-
Yuan X, Yu J, Gerber G, Chaturvedi S, Cole M, Chen H, Metjian A, Sperati CJ, Braunstein EM, Brodsky RA. Ex vivo assays to detect complement activation in complementopathies. Clin Immunol. 2020 12; 221:108616.
-
Thurman JM. Complement Biomarkers of Hemolytic Uremic Syndrome-If Not One Thing, Maybe Another. Mayo Clin Proc. 2018 10; 93(10):1337-1339.
-
Dixon BP, Gruppo RA. Atypical Hemolytic Uremic Syndrome. Pediatr Clin North Am. 2018 06; 65(3):509-525.
-
Vaught AJ, Braunstein EM, Jasem J, Yuan X, Makhlin I, Eloundou S, Baines AC, Merrill SA, Chaturvedi S, Blakemore K, Sperati CJ, Brodsky RA. Germline mutations in the alternative pathway of complement predispose to HELLP syndrome. JCI Insight. 2018 03 22; 3(6).
-
Fraga-Rodriguez GM, Brió-Sanagustin S, Turón-Viñas E, Dixon BP, Carreras-González E. Eculizumab in a child with atypical haemolytic uraemic syndrome and haemophagocytic lymphohistiocytosis triggered by cytomegalovirus infection. BMJ Case Rep. 2017 Apr 26; 2017.
-
Benamu E, Montoya JG. Infections associated with the use of eculizumab: recommendations for prevention and prophylaxis. Curr Opin Infect Dis. 2016 08; 29(4):319-29.
-
Cataland SR, Holers VM, Geyer S, Yang S, Wu HM. Biomarkers of terminal complement activation confirm the diagnosis of aHUS and differentiate aHUS from TTP. Blood. 2014 Jun 12; 123(24):3733-8.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|